Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam reported Q1 product revenue up 121% YoY to $1.04B, led by ATTR therapy sales up 153% to $910M, alongside EPS of $1.51 vs a $0.14 loss a year ago. Full-year 2026 net product revenue guidance is $4.9B–$5.3B (up 71% at the midpoint). Despite the stock down 24% YTD, analysts’ average price target of $436 implies ~45% upside, though the shares trade at ~75x trailing earnings and face potential pricing pressure risk.

Analysis

ALNY is less a single-product story than a platform monetization story, and the market will only keep paying up if the franchise keeps compounding outside the current orphan niche. The real lever is payer behavior: if cardiology adoption expands without heavy rebate pressure, operating leverage can remain unusually strong; if access is forced through, the multiple should compress even if revenue still grows.

The competitive read-through is most negative for BBIO and, to a lesser degree, PFE, because price competition in ATTR-CM would not just shift share, it would reset the category's net-price ceiling and slow ALNY's revenue-per-patient expansion. RHHBY looks like the cleaner beneficiary because it gets participation without bearing the full commercial burden, while the AI collaboration is mostly a long-duration R&D optionality rather than a near-term P&L driver.

Consensus may be underpricing execution risk over the next 1-3 quarters and overpricing certainty over the next 2-3 years. The stock can work if phase-3 data and launch metrics keep validating a multi-indication platform, but a single miss in cardiomyopathy uptake or a competitor pricing surprise would be enough to de-rate a rich biotech multiple quickly. Falsifiers: a cut to 2026 guidance, slower Amvuttra net-sales growth, or visible net-price erosion from BBIO/PFE pressure.

Key Decisions for Investors

• Long ALNY on pullbacks, not momentum: use post-rally weakness or any 5-8% dip to build a 6-12 month position; the risk/reward improves materially if the market is still valuing it like a growth biotech rather than a mature commercial platform.
• Relative-value trade: long ALNY / short BBIO for 1-3 months into cardiomyopathy and pricing catalysts. Thesis is that ALNY's platform breadth and moat can absorb competition better than BBIO's narrower ATTR-CM exposure; exit if BBIO starts taking share or ALNY net price trends down.
• If you want lower-beta exposure to the theme, prefer RHHBY as a partner beneficiary over PFE as a direct competitor. RHHBY offers upside to category expansion with less margin risk, while PFE is the cleaner short if you believe amyloid pricing comes under pressure.
• Do not buy ALNY calls unless implied volatility is cheap versus its 1-year range; if vol is elevated, equity or call spreads are a better expression than outright options.